WGO Graded Evidence: Management of Acute Viral Hepatitis

Level: Clinical Trials: 6 Abstracts

Legend:   : Special Mention  : Important  : Very Important  : Key Development
 
  A randomized controlled trial of lamivudine to treat acute hepatitis B.
M Kumar, S Satapathy, R Monga, K Das, S Hissar, C Pande, BC Sharma, SK Sarin, Hepatology. 2007 Jan:97-101
  Peginterferon alfa-2b therapy in acute hepatitis C: impact of onset of therapy on sustained virologic response.
SM Kamal, AE Fouly, RR Kamel, B Hockenjos, A Al Tawil, KE Khalifa, Q He, MJ Koziel, KM El Naggar, J Rasenack, NH Afdhal, Gastroenterology. 2006 Mar:632-8
  Duration of peginterferon therapy in acute hepatitis C: a randomized trial.
SM Kamal, KN Moustafa, J Chen, J Fehr, A Abdel Moneim, KE Khalifa, LA El Gohary, AH Ramy, MA Madwar, J Rasenack, NH Afdhal, Hepatology. 2006 May:923-31
Supplementary evidence:
  Short-term interferon-alfa therapy for acute hepatitis C: a randomized controlled trial.
H Nomura, S Sou, H Tanimoto, T Nagahama, Y Kimura, J Hayashi, H Ishibashi, S Kashiwagi, Hepatology. 2004 May:1213-9
  Three times weekly versus daily dose alpha-interferon treatment in patients with acute hepatitis C.
P Fabris, G Tositti, MT Giordani, D Infantolino, LF de, Am J Gastroenterol. 2002 Feb:492-3
  Treatment of acute hepatitis C with interferon alpha-2b: early initiation of treatment is the most effective predictive factor of sustained viral response.
J Delwaide, N Bourgeois, C Gérard, S De Maeght, F Mokaddem, E Wain, B Bastens, J Fevery, M Géhénot, O Le Moine, JP Martinet, G Robaeys, B Servais, M Van Gossum, H Van Vlierberghe, Belgian Association for the Study of the Liver (BASL), Aliment Pharmacol Ther. 2004 Jul 1:15-22